Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 5;12:4461–4468. doi: 10.2147/OTT.S210077

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Wang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Vitexin inhibited nasopharyngeal carcinoma cell growth in vivo. (A) NPC cells CNE1 (8×10⁶) were inoculated subcutaneously into nude mice. When tumors were palpable, mice were randomly divided into two groups (n=6/group). One group was orally administrated with vitexin (30 mg/kg) daily for continuous 2 weeks, and the other was given vehicle as a control group. Tumor volumes were monitored every other day. (B) At the end of the experiment, tumors were excised and taken photos. (C) Tumor weight was measured. (D) Body weight was also measured during the process. **p<0.01. (E) The excised tumors were lysed for immunoblotting against p-p65, p65 and Cyclin D1. GAPDH was used as an internal control.